

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MURRAY et al.

Serial No. 10/519,922

Filed: January 3, 2005



Atty. Ref.: 620-354

Group: unknown

Examiner: unknown

For: 3-'(HETERO) ARYLMETHOXY PYRIDINES AND THEIR
ANALOGUES AS P38 MAP KINASE INHIBITORS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**March 2, 2005**

Sir:

INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits] **N/C**
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] **N/C**
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] **\$180.00**
3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- a) The required Statement made in item 8 below; or
- b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- b) The required Statement is stated in item 8 below.
8. Statement under 37 CFR 1.97(e)
- a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By:



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

10 Rec'd PCT/PTO
04 MAR 2005

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		620-354	10/519,922
APPLICANT			
MURRAY et al.			
(Use several sheets if necessary)		FILING DATE	GROUP
		January 3, 2005	unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
EP 0 204 285 B1	01/1992	Europe				
EP 0 205 285 A1	12/1986	Europe				
EP 0 268 989 A1	06/1988	Europe				
EP 0 268 989 B1	06/1988	Europe				
EP 0 623 589 A1	11/1994	Europe				
EP 1 180 518 A1	02/2002	Europe				
JP 57-38777	03/1982	Japan				
WO 00/43773	07/2000	WIPO				
WO 00/55120	09/2000	WIPO				
WO 00/55139	09/2000	WIPO				
WO 00/55152	09/2000	WIPO				
WO 01/04115	01/2001	WIPO				
WO 01/12621	02/2001	WIPO				
WO 01/29041	04/2001	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Hall, et al., <i>Adv. Cancer Res.</i> , 68:67-108 (1996)
Minden, et al., <i>Biochimica et Biophysica Acta</i> , 1333:F85-F104 (1997)
Savelon, L., et al., <i>Bioorganic & Medicinal Chemistry</i> , 9, 133-142 (1998)
Burgess, G.S., et al., <i>Blood</i> , 92:2450-60 (1998)
Frey and Mulder, <i>Cancer Res.</i> 57, 628-633 (1997)
Hiles, et al., <i>Cell</i> , 70:419-429 (1992)
Kunz, et al., <i>Cell</i> , 73:585-596 (1993)
Rouse, et al., <i>Cell</i> 78, 1027-1037 (1994)
Nurse, <i>Cell</i> , 91:865-867 (1997)
Coghlan, et al., <i>Chemistry & Biology</i> , 7, 793-803 (2000)
Shokei, K., et al., <i>Circulation</i> , 97:1731-7 (1998)
Force, T., et al., <i>Circ. Res.</i> , 78:947-53 (1996)
Bogoyevitch, M.A., et al., <i>Circ. Res.</i> , 79:162-73 (1996)
Adams, J.W., et al., <i>Circ. Res.</i> , 83: 167-78 (1998)
O'Connor, <i>Cancer Surveys</i> , 29, 151-182 (1997)

*Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

CITATION

620-354

10/519,922

APPLICANT

MURRAY et al.

(Use several sheets if necessary)

FILING DATE

GROUP

January 3, 2005

unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
WO 01/57022	08/2001	WIPO				
WO 02/10146	02/2002	WIPO				
WO 02/081475	10/2002	WIPO				
WO 02/085859	10/2002	WIPO				
WO 92/20642	11/1992	WIPO				
WO 93/14081	07/1993	WIPO				
WO 93/14082	07/1993	WIPO				
WO 93/25571	12/1993	WIPO				
WO 96/23783	08/1996	WIPO				
WO 98/07425	02/1998	WIPO				
WO 98/52558	11/1998	WIPO				
WO 99/00357	01/1999	WIPO				
WO 00/43384	07/2000	WIPO				
WO 99/32433	07/1999	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Stover, et al., <i>Curr. Opin. Drug Disc. Dev.</i> , 2, 274-285 (1999)
	Toledo, et al., <i>Curr. Med. Chem.</i> , 6, 775-805 (1999)
	McMahon, et al., <i>Current Opinion in Drug Discovery & Development</i> , 1, 131-146 (1998)
	Adams, et al., <i>Curr. Opin. Drug Disc. Dev.</i> , 2, 96-109 (1999)
	Kim and Kimmel, <i>Curr. Opinion Genetics Dev.</i> , 10, 508-514 (2000)
	Kumar, S., et al., <i>Curr Opin Pharmacol.</i> , 1(3), 307-13 (2001)
	Hay, D.P. and Sarau, H.M., <i>Curr. Opin. Pharmacol.</i> , 1: 242-7 (2001)
	Garcia-Bustos, et al., <i>EMBO J.</i> , 13:2352-2361 (1994)
	Gupta, et al., <i>EMBO J.</i> , 15:2760-70 (1996)
	Bischoff, et al., <i>EMBO J.</i> , 17, 3052-3065 (1998)
	Wilson, D.J., et al., <i>Eur. J. Immunol.</i> , 26:989-94 (1996)
	van Seventer, G.A., et al., <i>Bur. J. Immunol.</i> , 28:3867-77 (1998)
	Strawn, et al., <i>Exp. Opin. Invest. Drugs</i> , 7, 553-573 (1998)
	Hanks, S.K., Hunter, T., <i>FASEB J.</i> , 9:576-596 (1995)
	Neufeld, et al., <i>FASEB J.</i> , 13, 9-22 (1999)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

10 Rec'd PCT/PTO 04 MAR 2005

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
CITATION		620-354	10/519,922
		APPLICANT	
		MURRAY et al.	
(Use several sheets if necessary)		FILING DATE	GROUP
		January 3, 2005	unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
WO 00/41698	07/2000	WIPO				
WO 00/38675	07/2000	WIPO				
WO 00/25791	05/2000	WIPO				
WO 00/18738	04/2000	WIPO				
WO 00/17175	03/2000	WIPO				
WO 99/65897	12/1999	WIPO				
WO 99/58502	11/1999	WIPO				
WO 99/32455	07/1999	WIPO				
WO 99/32463	07/1999	WIPO				
WO 99/32111	07/1999	WIPO				
WO 99/32436	07/1999	WIPO				
WO 99/15164	04/1999	WIPO				
WO 00/10563	03/2000	WIPO				
WO 00/55120	09/2000	WIPO				
WO 02/20642	03/2002	WIPO				
WO 99/32110	07/1999	WIPO				
WO 01/53274	07/2001	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Onishi, I., et al., <i>FEBS Lett.</i> , 420:201-4 (1997)
	Zwacka, R.M., et al., <i>Hepatology</i> , 28: 1022-30 (1998)
	Bjorbaek, et al., <i>J. Biol. Chem.</i> 270, 18848-18852 (1995)
	Kimura, et al., <i>J. Biol. Chem.</i> , 272, 13766-13771 (1997)
	Liang, F., et al., <i>J. Biol. Chem.</i> , 272:28050-6 (1997)
	Schumacher, et al., <i>J. Cell Biol.</i> , 143, 1635-1646 (1998)
	Haq, et al., <i>J. Cell Biol.</i> , 151, 117-129 (2000)
	Dinarello, <i>J. Clinical Immunology</i> , 5: 287-297 (1985)
	Xu, G., et al., <i>J. Clin. Invest.</i> , 97:508-14 (1996)
	Sivaraman, et al., <i>J. Clin. Invest.</i> 99, 1478-1483 (1997)
	Liu, Z-Y., et al., <i>J. Clin. Invest.</i> , 99:1798-804 (1997)
	Parola, M., et al., <i>J. Clin. Invest.</i> , 102:1942-50 (1998)

*Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.			
CITATION		620-354 APPLICANT	10/519,922			
(Use several sheets if necessary)		MURRAY et al. FILING DATE	GROUP			
		January 3, 2005	unknown			
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						TRANSLATION
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)						
	Nishina, H., et al., <i>J. Exp. Med.</i> , 186:941-53 (1997)					
	Shaw, J.T., et al., <i>J. Het. Chem.</i> , 17(1) 11-16 (1980)					
	Ponticello, G.S., et al., <i>J. Het. Chem.</i> , 17, 1980, 445-448 (Belstein 4435702)					
	Kempiaki, J.J., et al., <i>J. Immunol.</i> , 162:3176-87 (1999)					
	Lin, A.J., et al., <i>J. Med. Chem.</i> , 15, 615-618 (1972)					
	Kaminski, J., et al., <i>J. Med. Chem.</i> , 28(7), 1985, 876-892 (Belstein 4421226)					
	Marchi, E., et al., <i>J. Med. Chem.</i> , 28(7), 1985, 960-963 (Belstein 5938191)					
	Giannotti, D., et al., <i>J. Med. Chem.</i> , 34(4), 1356-1362 (1991)					
	Namikawa, K., et al., <i>The Journal of Neuroscience</i> , 20, 2875-2886 (2000)					
	Berge et al., 1977, "Pharmaceutically Acceptable Salts," <i>J. Pharm. Sci.</i> , Vol. 66, pp. 1-19					
	Badger, et al., <i>J. Pharm. Exp. Thera.</i> , 279: 1453-1461(1996)					
	Carpino, L.A., <i>J. Am. Chem. Soc.</i> , (1993), 115(10), 4397-8					
	Oarcfa-Echeverria, et al., <i>Med. Res. Rev.</i> , 20, 28-57 (2000)					
	Herlaar, E & Brown, Z., <i>Molecular Medicine Today</i> , 5: 439-447 (1999)					
	Raingeaud, et al., <i>Mol. Cell Biol.</i> 16, 1247-1255 (1996)					
	Martin, et al., <i>Brain Res. Mol. Brain Res.</i> , 35:47-57 (1996)					
	Anderson, et al., <i>Nature</i> 343, 651-652 (1990)					
	Yang et al., <i>Nature</i> , 389:865-870 (1997)					
	Zeng, et al., <i>Nature</i> , 395, 507-510 (1998)					
	Mohit, et al., <i>Neuron</i> , 14:67-78 (1995)					
	Behrens, A., et al., <i>Nat. Genet.</i> , 21:326-9 (1999)					
	Yuan, Z.Q., et al., <i>Oncogene</i> , 19, 2324-2330 (2000)					
	BoLEN, <i>Oncogene</i> , 8, 2025-2031 (1993)					
	Xu, X., et al., <i>Oncogene</i> , 13:135-142 (1996)					
	Griswold, et at., <i>Pharmacol. Comm.</i> , 7: 323-229 (1996)					
	Chen, et al., <i>Proc. Natl. Acad. Sci. USA</i> 90, 10952-10956 (1993)					

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-EB-A820 (Also PTO-1449)